인트론바이오

048530KOSDAQ기초 의약물질 제조업

58.8 / 100

Reference Date: 2026-06-10

Financial Score19.5 / 40

News Sentiment21.3 / 25

Momentum8.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but Revenue is on a declining trend. Declined 11.9% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

IntronBio focuses on developing biopharmaceuticals based on bacteriophage technology and molecular diagnostic solutions. The company's drug development division targets antibiotic-resistant bacterial infections and immune therapies, while its diagnostic division produces molecular test kits, including COVID-19 diagnostic products, contributing to revenue.

Number of Employees

77people

Average Salary

64.3M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 27.714.0Point

PBR

1.32Industry Average 1.744.0Point

In line with industry avg

ROE

-11.66Industry Average -6.033.5Point

1.9x industry avg (good)

Debt Ratio

0.52Industry Average 6.628.0Point

Half of industry avg (excellent)

Trend 2023~20250.0 / 10 points

Revenue Growth Rate

0.0 / 3

Avg ▼21.8% (2-year basis)

Operating Profit Growth Rate

0.0 / 3

Avg ▼55.2% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -8.0% (declining, 3yr)

Detailed News Sentiment

2 totalPositive 2Neutral 0Negative 0Average Sentiment Score 85

Positive
인트론바이오, 'SAL200' 기반 비강 항균제제 임상 1/2a상 IN...
인트론바이오의 SAL200 기반 비강 항균제제 임상 성공으로 HAI 예방 효과 기대, 비용 및 기간 절감 전략으로 시장 경쟁력 강화.
Positive
인트론바이오 "과수화상병 신약 'EAL2200' 강한 항균 효능 확인"
인트론바이오의 과수화상병 신약 'EAL2200'이 고농도에서 100% 사멸 효과를 보여 긍정적인 임상 결과를 시사합니다.

Detailed Momentum

52-week position1.0Point

Near 52w low (8%, downtrend)

Current 2,995Won52-week high 6,65052-week low 2,635

1-month return1.0Point

1m -11.91% (falling)

Volume trend6.0Point

Volume surge

Detailed Disclosure

1 totalPositive 0Neutral 1Negative 0

Neutral분기보고서 (2026.03)2026-05-14